Kevenix

Desloratadine, the active ingredient in Kevenix, is a second‑generation H1‑antihistamine presented as an oral dosage form for oral use. It is employed to relieve symptoms of allergic conditions such as allergic rhinitis and chronic idiopathic urticaria in adults and children when appropriate.

GNH USA supplies Kevenix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Desloratadine acts on histamine‑mediated allergic pathways and is clinically used for the following conditions: - Allergic rhinitis: Reduces nasal congestion, sneezing, itching and rhinorrhea. - Seasonal allergic rhinitis: Provides symptom relief during pollen seasons. - Chronic idiopathic urticaria: Decreases frequency and severity of hives and associated itching. - Allergic conjunctivitis: Alleviates eye itching, redness and tearing.

Desloratadine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: transient sensation of oral dryness. - Fatigue: feeling of tiredness without exertion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm reported in rare cases. - Stevens‑Johnson syndrome: severe skin reaction, extremely rare.

Before prescribing desloratadine, clinicians should consider the following precautions: - Assess renal function: adjust dosage in patients with severe renal impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Known hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy and lactation: consult healthcare professional before use. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Desloratadine may interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase desloratadine plasma levels. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): can raise drug exposure. - Alcohol: additive central nervous system depression may occur.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance dry‑mouth effects. - Other antihistamines: risk of cumulative sedation. - Theophylline: possible alteration of plasma concentrations.